<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>235-FLUOROURACIL-(AND,-BY-EXTRAPOLATION,-OTHER-FLUOROPYRIMIDINES).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)" code="L01BC-001" /></DRUG1>
<DRUG2>
<DRUG name="FOLINIC ACID" rxcui="6313">
<ATC code="B03BB" />
<ATC code="B03BB01" />
<ATC code="B03BB51" />
</DRUG>
</DRUG2>
<DESCRIPTION>Strengthening of the effects, both cytostatic and undesirable, of the fluorouracil. </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>235-FLUOROURACIL-(AND,-BY-EXTRAPOLATION,-OTHER-FLUOROPYRIMIDINES).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)" code="L01BC-001" /></DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If taking these medications together cannot be avoided, more frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the cytotoxic and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>235-FLUOROURACIL-(AND,-BY-EXTRAPOLATION,-OTHER-FLUOROPYRIMIDINES).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)" code="L01BC-001" /></DRUG1>
<DRUG2>
<DRUG name="INTERFERON ALFA" rxcui="1431112">
<ATC code="L03AB01" />
<ATC code="5879" />
<ATC code="L03AB04" />
<ATC code="5880" />
<ATC code="L03AB05" />
<ATC code="202912" />
<ATC code="L03AB06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the gastrointestinal toxicity of the fluorouracil</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>235-FLUOROURACIL-(AND,-BY-EXTRAPOLATION,-OTHER-FLUOROPYRIMIDINES).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)" code="L01BC-001" /></DRUG1>
<DRUG2>
<DRUG name="METRONIDAZOLE" rxcui="6922">
<ATC code="A02BD08" />
<ATC code="A02BD03" />
<ATC code="A02BD02" />
<ATC code="A01AB17" />
<ATC code="D06BX01" />
<ATC code="G01AF01" />
<ATC code="J01XD01" />
<ATC code="P01AB01" />
<ATC code="A02BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the toxicity of the fluourouracil due to decrease of its clearance</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>235-FLUOROURACIL-(AND,-BY-EXTRAPOLATION,-OTHER-FLUOROPYRIMIDINES).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)" code="L01BC-001" /></DRUG1>
<DRUG2>
<DRUG name="ORNIDAZOLE" rxcui="7701">
<ATC code="G01AF06" />
<ATC code="J01XD03" />
<ATC code="P01AB03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the toxicity of the fluorouracil due to decrease of its clearance</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
</INTERACTIONS>
